RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial
Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3151-3162
DOI: 10.1200/jco-26-00725 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Rashmi Chugh und 26 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Rogel Comprehensive Cancer Center, Ann Arbor, MI. Hauptthemen laut MEDLINE: Desmoid Tumors, Amyloid Precursor Protein Secretases. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Desmoid tumors (DTs) are rare, often locally aggressive, connective tissue neoplasms with limited effective treatment options. We evaluated the safety and efficacy of varegacestat, an oral gamma-secretase inhibitor. METHODS RINGSIDE phase II was an open-label, randomized, dose-finding trial of varegacestat in adults with histologically confirmed DT and disease progression. Participants were randomly assigned 1:1:1 to oral varegacestat 1.2-mg once-daily, 2-mg intermittent (once daily for 2 consecutive days with 5 consecutive days off), or 4-mg intermittent dose. The primary end point was safety. The secondary end point was change in tumor volume from baseline to week 16 per blinded independent central review. At the study end, participants who entered the open-label extension received the selected phase III dose (1.2 mg once daily). RESULTS In total, 42 participants enrolled in the randomized trial (14 per dose arm). Median varegacestat exposure was 50.5 (range, 3.0-76.0) weeks. Forty-one (97.6%) participants reported treatment-related adverse events (AEs), of which 9 (21.4%) reported grade 3 AEs and none reported serious AEs. There were no grade 4/5 events. The median tumor volume reduction at week 16 was –51.91% for the 1.2-mg once-daily dose, –15.25% for the 2-mg intermittent dose and –9.50% for the 4-mg intermittent dose. The confirmed objective response rate (ORR) was 35.7%, 21.4%, and 21.4%, respectively. Among 29 (69%) participants who entered the open-label extension and received 1.2 mg once daily (median exposure, 102.0 [range, 3.0-169.0] weeks), the median best percent tumor volume change was –85.88% and the confirmed ORR increased to 57.1%. CONCLUSION Varegacestat demonstrated clinically meaningful DT volume reduction and ORR with a manageable safety profile across dose regimens. The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Michigan Rogel Comprehensive Cancer Center, Ann Arbor, MI.
- University of California Los Angeles, Los Angeles, CA.
- Princess Alexandra Hospital and Icon Cancer Centre, South Brisbane, Australia.
- Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, PA.
- Endeavor Health Cancer Institute, Evanston, IL.
- Stanford Health Care, Stanford, CA.
ORCID-Profile: Rashmi Chugh, Vladimir Andelkovic, Atrayee Basu Mallick, Bruce Brockstein, Nam Bui, Edwin Choy, Lara E Davis, Mrinal Gounder, Shadi Haddadin, Bernd Kasper, Hyo Song Kim, Alexander Lee, Jeremy Lewin, Nadia Hindi, Prabhjot Mundi, Ravin Ratan, Winette van der Graaf, Robin L Jones
Zitieren
APA
Chugh, R., Singh, A., Andelkovic, V., Mallick, A. B., Brockstein, B., Bui, N., Chawla, S., Choy, E., Davis, L. E., Gounder, M., Haddadin, S., Kasper, B., Kim, H. S., Lee, A., Lewin, J., Hindi, N., Mundi, P., Ratan, R., van der Graaf, W., …, & RINGSIDE Phase II Study Investigators (2026). RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial. Journal of Clinical Oncology, 44(32), 3151-3162. https://doi.org/10.1200/jco-26-00725
Vancouver
Chugh R, Singh A, Andelkovic V, Mallick AB, Brockstein B, Bui N, et al. RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial. Journal of Clinical Oncology. 2026;44(32):3151-3162. doi:10.1200/jco-26-00725
BibTeX
@article{Chugh2026,
author = {Chugh, Rashmi and Singh, Arun and Andelkovic, Vladimir and Mallick, Atrayee Basu and Brockstein, Bruce and Bui, Nam and Chawla, Sant and Choy, Edwin and Davis, Lara E and Gounder, Mrinal and Haddadin, Shadi and Kasper, Bernd and Kim, Hyo Song and Lee, Alexander and Lewin, Jeremy and Hindi, Nadia and Mundi, Prabhjot and Ratan, Ravin and van der Graaf, Winette and Yoon, Janet and Birrenkott, Matthew and Fetterly, Gerald and Newhall, Katie and Song, Eric and Yovell, Jonathan and Jones, Robin L and RINGSIDE Phase II Study Investigators, RINGSIDE Phase II Study Investigators},
title = {RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {32},
pages = {3151--3162},
doi = {10.1200/jco-26-00725}
}
EUVIMED